StocksMedium•16 November 2026•
1 min read
EU Approves Incyte Oral Treatment for Chronic Skin Disease
Key Facts
1Incyte announced that the European Union has approved its oral treatment for a chronic skin disease.
Incyte announced that the European Union has approved its oral treatment for a chronic skin disease. Reuters reported that the approval follows a regulatory review process by European health authorities for the company's dermatological treatment.
INCY closed at $120.97 on November 13, 2026, with the stock reaching a day high of $122.07 and a low of $119.72 during that session. Regulatory approval in a major market like the EU represents a significant milestone for biotech firms, directly impacting revenue potential.